ZA986893B - Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same - Google Patents

Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same

Info

Publication number
ZA986893B
ZA986893B ZA986893A ZA986893A ZA986893B ZA 986893 B ZA986893 B ZA 986893B ZA 986893 A ZA986893 A ZA 986893A ZA 986893 A ZA986893 A ZA 986893A ZA 986893 B ZA986893 B ZA 986893B
Authority
ZA
South Africa
Prior art keywords
procedure
compound
pharmaceutical preparation
oral pharmaceutical
making same
Prior art date
Application number
ZA986893A
Other languages
English (en)
Inventor
Carlos Picornell Darder
Original Assignee
Intexim S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8300432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA986893(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intexim S A filed Critical Intexim S A
Publication of ZA986893B publication Critical patent/ZA986893B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA986893A 1997-07-31 1998-07-31 Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same ZA986893B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701816A ES2137862B1 (es) 1997-07-31 1997-07-31 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.

Publications (1)

Publication Number Publication Date
ZA986893B true ZA986893B (en) 1999-01-27

Family

ID=8300432

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986893A ZA986893B (en) 1997-07-31 1998-07-31 Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same

Country Status (33)

Country Link
US (1) US20020098242A1 (xx)
EP (1) EP1010423B1 (xx)
JP (1) JP3961217B2 (xx)
KR (1) KR100591488B1 (xx)
AR (1) AR013242A1 (xx)
AT (1) ATE317688T1 (xx)
AU (1) AU751609B2 (xx)
BG (1) BG64967B1 (xx)
CA (1) CA2307037C (xx)
CR (1) CR5826A (xx)
CZ (1) CZ298700B6 (xx)
DE (1) DE69833490T2 (xx)
DK (1) DK1010423T3 (xx)
ES (3) ES2137862B1 (xx)
GT (1) GT199800113A (xx)
HN (1) HN1998000113A (xx)
HR (1) HRP20000053B1 (xx)
HU (1) HU230635B1 (xx)
IL (1) IL134158A (xx)
MY (1) MY121353A (xx)
NO (1) NO20000435L (xx)
NZ (1) NZ502590A (xx)
PA (1) PA8456401A1 (xx)
PE (1) PE105199A1 (xx)
PL (1) PL192961B1 (xx)
PT (1) PT1010423E (xx)
RU (1) RU2207114C2 (xx)
SK (1) SK284892B6 (xx)
TR (1) TR200000264T2 (xx)
TW (1) TW533201B (xx)
UA (1) UA66800C2 (xx)
WO (1) WO1999006032A2 (xx)
ZA (1) ZA986893B (xx)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR100447085B1 (ko) * 2001-11-08 2004-09-04 바램제약주식회사 마그네슘이온, 칼슘이온 또는 철이온이 고농도로 결합된알긴산의 제조 방법
AP1919A (en) * 2001-11-21 2008-11-13 Eisai R&D Man Co Ltd Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
CA2494716A1 (en) * 2002-08-02 2004-02-19 Ratiopharm Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
WO2004041195A2 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
WO2005097082A1 (en) * 2004-03-31 2005-10-20 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
CA2581816A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
MX2007004741A (es) 2004-10-21 2007-09-07 Eurand Pharmaceuticals Ltd Composiciones farmaceuticas con sabor enmascarado con formadores de poro gastrosolubles.
BRPI0500586A (pt) * 2005-02-21 2006-10-10 Fundacao Oswaldo Cruz composição farmacêutica, processo para preparar dita composição, uso da respectiva composição no tratamento da imunodeficiência causada por infecção pelo hiv e respectivo método de tratamento
WO2006111980A2 (en) * 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2006274835B2 (en) 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
SG186648A1 (en) 2007-02-20 2013-01-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
CA2683409A1 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
ES2963291T3 (es) * 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
US20100239665A1 (en) * 2007-05-01 2010-09-23 Ivan Coulter Pharmaceutical nimodipine compositions
CA2704826A1 (en) * 2007-11-27 2009-06-04 Ohara Pharmaceutical Co., Ltd. Method for producing granulated preparation
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
EP2432455B1 (en) 2009-05-18 2014-11-12 Sigmoid Pharma Limited Composition comprising oil drops
CA2770570A1 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
JP6043929B2 (ja) 2010-10-01 2016-12-14 アラガン ファーマシューティカルズ インターナショナル リミテッド 腸溶コーティングされた低力価パンクレリパーゼ製剤
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20120328697A1 (en) * 2011-06-01 2012-12-27 Fmc Corporation Controlled Release Solid Dose Forms
US10953025B2 (en) * 2011-07-14 2021-03-23 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
CN103945832B (zh) * 2011-07-14 2017-03-29 能脑有限责任公司 用于脑能量分子延迟释放和持续释放的组合物，装置及方法
EP2987499B1 (en) 2011-08-08 2019-05-08 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
JP2016537387A (ja) 2013-08-09 2016-12-01 アラガン ファーマシューティカルズ インターナショナル リミテッド 経腸投与に適した消化酵素組成物
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
MX2014008314A (es) * 2014-07-07 2016-01-06 Andres Abelino Choza Romero Procedimiento para mezclar sustancias, mediante nebulizacion.
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
PL3215127T3 (pl) 2014-11-07 2021-05-17 Sublimity Therapeutics Limited Kompozycje zawierające cyklosporynę
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
UA66800C2 (uk) 2004-06-15
EP1010423A2 (en) 2000-06-21
TW533201B (en) 2003-05-21
HU230635B1 (hu) 2017-05-29
DE69833490D1 (de) 2006-04-20
ES2137862B1 (es) 2000-09-16
KR100591488B1 (ko) 2006-06-22
ES2156699A1 (es) 2001-07-01
CA2307037A1 (en) 1999-02-11
WO1999006032A3 (es) 1999-08-12
HUP0002524A2 (hu) 2001-08-28
WO1999006032A2 (es) 1999-02-11
IL134158A0 (en) 2001-04-30
CZ298700B6 (cs) 2007-12-27
HUP0002524A3 (en) 2002-12-28
PL338613A1 (en) 2000-11-06
IL134158A (en) 2004-08-31
NO20000435L (no) 2000-03-23
BG64967B1 (bg) 2006-11-30
US20020098242A1 (en) 2002-07-25
HRP20000053A2 (en) 2000-08-31
SK1032000A3 (en) 2000-11-07
CA2307037C (en) 2006-09-12
CZ2000344A3 (cs) 2000-06-14
AU8217398A (en) 1999-02-22
PT1010423E (pt) 2006-06-30
PE105199A1 (es) 1999-11-19
CR5826A (es) 1998-09-28
ES2137862A1 (es) 1999-12-16
AU751609B2 (en) 2002-08-22
NZ502590A (en) 2001-08-31
PA8456401A1 (es) 2000-09-29
RU2207114C2 (ru) 2003-06-27
HRP20000053B1 (en) 2003-10-31
ES2256943T4 (es) 2007-09-16
JP2001511443A (ja) 2001-08-14
EP1010423B1 (en) 2006-02-15
AR013242A1 (es) 2000-12-13
HN1998000113A (es) 2000-01-06
TR200000264T2 (tr) 2000-09-21
BG104193A (en) 2000-09-29
MY121353A (en) 2006-01-28
KR20010022439A (ko) 2001-03-15
DK1010423T3 (da) 2006-05-22
NO20000435D0 (no) 2000-01-27
JP3961217B2 (ja) 2007-08-22
PL192961B1 (pl) 2006-12-29
GT199800113A (es) 2000-01-18
SK284892B6 (sk) 2006-02-02
DE69833490T2 (de) 2006-10-19
ES2156699B1 (es) 2002-03-01
ATE317688T1 (de) 2006-03-15
ES2256943T3 (es) 2006-07-16

Similar Documents

Publication Publication Date Title
ZA986893B (en) Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same
HUP0103708A3 (en) Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
EG24044A (en) pharmaceutical formulation of omeprazole
IL131818A (en) Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and solvates and their preparation
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
HUP9903308A3 (en) Granuls for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
EG21973A (en) A new process for the preparation of a pharmacolgically active substance
IL191582A0 (en) Polymorph of a pharmaceutical
HU9502918D0 (en) Pharmaceutical composition of antihypertriglyceridemic activity
PL332249A1 (en) Pharmaceutical microspheres of varproinic acid for oral administration
HUP9800573A3 (en) Rapamycin formulations for oral administration and process for their preparation
PL307469A1 (en) Preparation for oral administration
HU9502426D0 (en) Compounds of pharmaceutical activity
ZA986320B (en) A method for the preparation of tertiary amines a compound useful therefor and alpha-2-receptor active tetrahyd-roisoquinoline derivatives
ZA987538B (en) A process for the preparation of solid oral dosage forms comprising alendronic acid
AU8885298A (en) Sustained-release oral preparation
SI1103252T1 (en) Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
AU5384798A (en) Process for preparation of 4-deoxyerythromycins a and b
HU9700442D0 (en) Compounds of pharmaceutical activity
TJ217R3 (en) A method for the preparation of a substance having cholagogic and anti-inflammatory activity
HU9701917D0 (en) New compound of medicinal activity
AU6224299A (en) Pharmaceutical intermediate for the synthesis of fluoxetine and a process for the preparation thereof
TJ218R3 (en) A method for the preparation of a substance having cholagogic activity
TJ213R3 (en) A method for the preparation of a substance having immunostimulate activity
GB9408369D0 (en) Oral administration of protein drugs